APA (7th ed.) Citation

Hemelrijck, M. V., Grisanti, S., Aujayeb, A., Forster, M., Mountzios, G., Napolitano, A., . . . Hejleh, T. A. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Hemelrijck, Mieke Van, et al. Determinants of 5-year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-real 5Y Global Registry. BMJ Publishing Group.

MLA (9th ed.) Citation

Hemelrijck, Mieke Van, et al. Determinants of 5-year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-real 5Y Global Registry. BMJ Publishing Group.